Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NiproTSE:8086 +0.39%70 OCF Yield % is 21.67 as of Jul. 14, 2026. GuruFocus rates TSE:8086 with a GF Score™ of 70/100 and a GF Value™ of 円1,457.04 (Fairly Valued). The stock has 6 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Nipro ranks better than 96.83% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Nipro's OCF Yield % or its related term are showing as below:
TSE:8086'
s OCF Yield % Range Over the Past 10 Years
Min: 21.67 Med: 0 Max: 21.67
Current: 21.67
During the past 13 years, the highest OCF Yield % of Nipro was 21.67%. The lowest was 21.67%. And the median was %.
TSE:8086's OCF Yield % is ranked better than 96.83% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 1.715
vs TSE:8086: 21.67
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Nipro OCF Yield % Related Terms
Nipro OCF Yield % Historical Data
* Premium members only.
The historical data trend for Nipro's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:8086 vs ISRG, BDX, MDLN: OCF Yield % Comparison
For the Medical Instruments & Supplies subindustry, Nipro's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nipro OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nipro's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Nipro's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro (TSE:8086) has a OCF Yield % of 21.67 as of Jul. 14, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Nipro and its competitors. Over the past decade, Nipro's OCF Yield % has ranged from 21.67 to 21.67. According to the industry distribution chart, Nipro ranks #27 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 3.2%.
Is Nipro's OCF Yield % too high?
Nipro's current OCF Yield % is 21.67. Over the past 10 years, this metric has ranged from a low of 21.67 to a high of 21.67. The Medical Devices & Instruments industry median OCF Yield % is 1.72. Nipro's value of 21.67 is 1163.6% above this industry median. Based on the distribution chart, Nipro ranks #27 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nipro has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nipro's OCF Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nipro ranks #27 out of 852 companies for OCF Yield %. This places Nipro in the top 3% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 1.72. Nipro's value of 21.67 is 1163.6% above this benchmark. Historically, Nipro's own OCF Yield % has ranged from 21.67 to 21.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.72, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nipro's current OCF Yield % of 21.67 is 1163.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Nipro and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nipro's current OCF Yield % is 21.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Based on GuruFocus' analysis, Nipro (TSE:8086) is currently considered Fairly Valued. The stock's GF Value™ is 円1,457.04, compared to a current price of 円1,552.50 — trading 6.6% above its estimated fair value. The current OCF Yield % is 21.67 and 1163.6% above the Medical Devices & Instruments industry median of 1.72. Nipro's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Nipro (TSE:8086), the current OCF Yield % is 21.67 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (TSE:8086) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be overvalued.
The current stock price of 円1,552.50 is trading 6.6% above its estimated GF Value™ of 円1,457.04.
GuruFocus considers Nipro to be Fairly Valued.
Key valuation signals for TSE:8086:
OCF Yield %: 21.67
GF Value™: 円1,457.04 vs. price of 円1,552.50 (6.6% above fair value)
Industry Position: 1163.6% above the Medical Devices & Instruments median (#27 of 852)
No single metric tells the full story. See the TSE:8086 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
70GF Score
Get the complete analysis for TSE:8086
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:8086 has been successfully added to your 
